In a model of depression, zileuton significantly improved depressive‐like behavior by suppressing hippocampal TNF α, IL-1β, nuclear NF-κB p65 and microglial activation, reducing neuronal apoptosis and restoring synaptic proteins and neurogenesis (Liu et al., 2020). This evidence concerns the gene IL1B and depressive symptom measurement.